Summer/winter changes in serum S100B protein concentration as a source of research variance

Fumero, Armando Morera; Abreu-González, Pedro; Henry-Benitez, M.; Yelmo-Cruz, S.; Díaz-Mesa, E.

doi:10.1016/j.jpsychires.2013.03.001

Cited by 14 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent literature has demonstrated a clinically relevant difference in serum S100B levels based on race and regional/seasonal variance, where individuals of a darker complexion have been reported to have higher steady-state S100B levels than those of lighter complexion (i.e., Caucasians during summer compared to winter in the Northern hemisphere [32], or individuals of African–American (A–A) compared to Caucasian descent [30, 33]). It was initially believed that ethnicity is the main driving force for elevated S100B in African–American subjects [30, 33].…”

Section: Resultsmentioning

confidence: 99%

Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers

Dadas

Washington

Marchi

et al. 2016

Fluids Barriers CNS

View full text Add to dashboard Cite

BackgroundBlood biomarkers of neurovascular damage are used clinically to diagnose the presence severity or absence of neurological diseases, but data interpretation is confounded by a limited understanding of their dependence on variables other than the disease condition itself. These include half-life in blood, molecular weight, and marker-specific biophysical properties, as well as the effects of glomerular filtration, age, gender, and ethnicity. To study these factors, and to provide a method for markers’ analyses, we developed a kinetic model that allows the integrated interpretation of these properties.MethodsThe pharmacokinetic behaviors of S100B (monomer and homodimer), Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase L1 were modeled using relevant chemical and physical properties; modeling results were validated by comparison with data obtained from healthy subjects or individuals affected by neurological diseases. Brain imaging data were used to model passage of biomarkers across the blood–brain barrier.ResultsOur results show the following: (1) changes in biomarker serum levels due to age or disease progression are accounted for by differences in kidney filtration; (2) a significant change in the brain-to-blood volumetric ratio, which is characteristic of infant and adult development, contributes to variation in blood concentration of biomarkers; (3) the effects of extracranial contribution at steady-state are predicted in our model to be less important than suspected, while the contribution of blood–brain barrier disruption is confirmed as a significant factor in controlling markers’ appearance in blood, where the biomarkers are typically detected; (4) the contribution of skin to the marker S100B blood levels depends on a direct correlation with pigmentation and not ethnicity; the contribution of extracranial sources for other markers requires further investigation.ConclusionsWe developed a multi-compartment, pharmacokinetic model that integrates the biophysical properties of a given brain molecule and predicts its time-dependent concentration in blood, for populations of varying physical and anatomical characteristics. This model emphasizes the importance of the blood–brain barrier as a gatekeeper for markers’ blood appearance and, ultimately, for rational clinical use of peripherally-detected brain protein.Electronic supplementary materialThe online version of this article (doi:10.1186/s12987-016-0045-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers

Dadas

Washington

Marchi

et al. 2016

Fluids Barriers CNS

View full text Add to dashboard Cite

show abstract

“…Finally, although the underlining regulatory mechanisms remain obscure, expression patterns depending on the cell cycle phases were observed for S100A6 in 3T3 cells [ 74 ], while seasonal- [ 75 ] and gender-dependent [ 75 , 76 ] serum concentrations of S100B protein were reported in humans.…”

Section: Structure Expression and Regulation Of S100 Proteinsmentioning

confidence: 99%

S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma

Delangre

Oppliger

Berkcan

et al. 2022

IJMS

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent and slow progressing hepatic pathology characterized by different stages of increasing severity which can ultimately give rise to the development of hepatocellular carcinoma (HCC). Besides drastic lifestyle changes, few drugs are effective to some extent alleviate NAFLD and HCC remains a poorly curable cancer. Among the deregulated molecular mechanisms promoting NAFLD and HCC, several members of the S100 proteins family appear to play an important role in the development of hepatic steatosis, non-alcoholic steatohepatitis (NASH) and HCC. Specific members of this Ca2+-binding protein family are indeed significantly overexpressed in either parenchymal or non-parenchymal liver cells, where they exert pleiotropic pathological functions driving NAFLD/NASH to severe stages and/or cancer development. The aberrant activity of S100 specific isoforms has also been reported to drive malignancy in liver cancers. Herein, we discuss the implication of several key members of this family, e.g., S100A4, S100A6, S100A8, S100A9 and S100A11, in NAFLD and HCC, with a particular focus on their intracellular versus extracellular functions in different hepatic cell types. Their clinical relevance as non-invasive diagnostic/prognostic biomarkers for the different stages of NAFLD and HCC, or their pharmacological targeting for therapeutic purpose, is further debated.

show abstract

“…Second, seasonality, the variation between seasons in the level of the biological variable. Melatonin [ 4 ], S100B protein [ 5 ] and malondialdehyde [ 6 ] are some molecules that show seasonal changes in their levels.…”

Section: Introductionmentioning

confidence: 99%

Day/Night and Summer/Winter Changes in Serum Total Antioxidant Capacity

Fumero

Abreu-González

Henry-Benitez

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: Seasonal and circadian changes are two factors described to affect blood levels of some biological molecules. The Total Antioxidant Capacity (TAC) is one global measure of the antioxidant capacity of a system. There is no agreement about the existence of day/night changes in TAC levels as well as there is no information about seasonal changes in TAC levels.Objective: The aims of this research are studying if there are summer/winter changes in TAC con-centrations or if TAC concentrations have day/night changes.Method: Ninety-eight healthy subjects took part in the summer study of whom 64 participated in the winter one. Blood was sampled at 09:00, 12:00 and 00:00 h. TAC was measured by the ABTS radi-cal cation technique. Results are expressed in mmol/L of trolox equivalents.Results: The subjects had significantly higher TAC levels in summer than winter at the three-time point studied. Summer 09:00 TAC concentration was significantly higher than the 12:00 and 00:00 h concentrations (1.34±0.26 vs 0.83±0.19, 0.75±0.18). Summer TAC 12:00 h concentrations were significantly higher than the 00:00 h concentrations (0.83±0.19 vs. 0.75±0.18). Winter 09:00 TAC concentrations were significantly higher than the 12:00 and 00:00 h concentrations (1.24±0.16 vs. 0.73±0.10, 0.67±0.13). There were no significant differences between the 12:00 and 00:00 h TAC concentrations.Conclusion: Strong methodological biases may be made if the seasonal and circadian changes in se-rum TAC concentration are not taken into account when researching in this area.

show abstract

Summer/winter changes in serum S100B protein concentration as a source of research variance

Cited by 14 publications

References 21 publications

Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers

Improving the clinical management of traumatic brain injury through the pharmacokinetic modeling of peripheral blood biomarkers

S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma

Day/Night and Summer/Winter Changes in Serum Total Antioxidant Capacity

Contact Info

Product

Resources

About